Detalles de la búsqueda
1.
A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer.
Oncologist
; 28(3): 230-238, 2023 03 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36811382
2.
Effect of Food and a Proton-Pump Inhibitor on the Absorption of Encorafenib: An In Vivo-In Vitro-In Silico Approach.
Mol Pharm
; 20(5): 2589-2599, 2023 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37037186
3.
A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.
Cancer
; 123(23): 4617-4630, 2017 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28817190
4.
First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors.
Invest New Drugs
; 33(2): 440-9, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25684345
5.
A phase I, single-center, open-label study to investigate the absorption, distribution, metabolism and excretion of encorafenib following a single oral dose of 100 mg [14 C] encorafenib in healthy male subjects.
Pharmacol Res Perspect
; 11(5): e01140, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37775918
6.
First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors.
Cancers (Basel)
; 16(1)2023 Dec 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38201519
7.
A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias.
Cancer
; 118(14): 3556-64, 2012 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22139909
8.
An exploratory, randomized, parallel-group, open-label, relative bioavailability study with an additional two-period crossover food-effect study exploring the pharmacokinetics of two novel formulations of pexmetinib (ARRY-614).
Clin Pharmacol
; 7: 87-95, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26491375
9.
Utilizing physiologically based pharmacokinetic modeling to inform formulation and clinical development for a compound with pH-dependent solubility.
J Pharm Sci
; 104(4): 1522-32, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25641187
10.
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
J Clin Oncol
; 26(13): 2139-46, 2008 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18390968
Resultados
1 -
10
de 10
1
Próxima >
>>